No recent analyst price targets found for TXMD.
Latest News for TXMD
TherapeuticsMD Announces Second Quarter 2026 Financial Results
TherapeuticsMD, Inc. (âTherapeuticsMDâ or the âCompanyâ) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financia
TherapeuticsMD Announces Second Quarter 2026 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2026. Second Quarter 2026 Financial Results Net Income from Continuing Operations Net income from continuing operations totaled $164 thousand, compared to net income of $545 thousand for…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TXMD.
U.S. House Trading
No House trades found for TXMD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.